Fig. 1 | Scientific Reports

Fig. 1

From: ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma

Fig. 1

ALKBH5 is downregulated in HCC and correlates with a poor prognosis. (A) Representative images of ALKBH5 IHC staining in HCC tissues and adjacent non-tumor tissues. (B) IHC scores of ALKBH5 staining in HCC tissues and adjacent nontumor tissues (n = 50). (C) Correlation analysis of ALKBH5 level and clinical features. (D-E) The OS and PFS analysis of patients between low-ALKBH5 and high-ALKBH5 groups. (F) Analysis of differentially expressed ALKBH5 in the HCC-based GSE6764 dataset. (G-H) Kaplan‒Meier analysis showing the OS (left) and PFS (right) of HCC patients based on ALKBH5 expression in TCGA databases. (*P < 0.05, **P < 0.01, ***P < 0.001).

Back to article page